Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, antihypertensive, digestive system, central nervous diseases, and respiratory preparations. The company was founded in 2001 and is based in … Read more
Market Cap & Net Worth: Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A (SHE:002940) has a market capitalization of $838.83 Million (CN¥6.15 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11391 globally and #2680 in its home market, demonstrating a -1.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Anglikang Pharmaceutical Co Ltd Class A's stock price CN¥30.51 by its total outstanding shares 201728186 (201.73 Million).
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Market Cap History: 2018 to 2026
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market capitalization history from 2018 to 2026. Data shows growth from $426.98 Million to $838.83 Million (10.65% CAGR).
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.24x
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap is 0.24 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
4.51x
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap is 4.51 times its annual earnings
9.89x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $426.98 Million | $1.26 Billion | $108.70 Million | 0.34x | 3.93x |
| 2019 | $365.11 Million | $1.40 Billion | $112.27 Million | 0.26x | 3.25x |
| 2020 | $514.08 Million | $1.29 Billion | $163.72 Million | 0.40x | 3.14x |
| 2021 | $457.97 Million | $1.38 Billion | $119.84 Million | 0.33x | 3.82x |
| 2022 | $498.38 Million | $1.57 Billion | $127.30 Million | 0.32x | 3.92x |
| 2023 | $588.81 Million | $1.62 Billion | $138.37 Million | 0.36x | 4.26x |
| 2024 | $362.37 Million | $1.51 Billion | $80.33 Million | 0.24x | 4.51x |
Competitor Companies of 002940 by Market Capitalization
Companies near Zhejiang Anglikang Pharmaceutical Co Ltd Class A in the global market cap rankings as of March 19, 2026.
Key companies related to Zhejiang Anglikang Pharmaceutical Co Ltd Class A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap moved from $426.98 Million to $ 838.83 Million, with a yearly change of 10.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥838.83 Million | -8.98% |
| 2025 | CN¥921.59 Million | +154.32% |
| 2024 | CN¥362.37 Million | -38.46% |
| 2023 | CN¥588.81 Million | +18.14% |
| 2022 | CN¥498.38 Million | +8.82% |
| 2021 | CN¥457.97 Million | -10.91% |
| 2020 | CN¥514.08 Million | +40.80% |
| 2019 | CN¥365.11 Million | -14.49% |
| 2018 | CN¥426.98 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Zhejiang Anglikang Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $838.83 Million USD |
| MoneyControl | $838.83 Million USD |
| MarketWatch | $838.83 Million USD |
| marketcap.company | $838.83 Million USD |
| Reuters | $838.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.